Is Thymosin Alpha-1 Legal in South Carolina?

What Is Thymosin Alpha-1 and Why Does Its Legal Status Matter?

Thymosin Alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5, first isolated and sequenced by Allan Goldstein's group at George Washington University in the 1970s. The synthetic version, thymalfasin, is marketed as Zadaxin by SciClone Pharmaceuticals and is approved in more than 35 countries for hepatitis B, hepatitis C, and as an adjuvant in non-small cell lung cancer, but the FDA has not granted it approval in the United States [1].

That single fact drives every legal question South Carolina patients ask. Because TA-1 lacks FDA approval, it cannot be dispensed as a finished pharmaceutical product in the U.S. Through normal channels. Instead, access depends entirely on the federal compounding framework and state-level pharmacy law.

The Immune-Modulation Evidence Base

A 2020 meta-analysis published in JAMA Network Open (N=3,512 across 11 randomized trials) found that thymalfasin significantly reduced 28-day all-cause mortality in sepsis patients compared with standard care, with an odds ratio of 0.54 (95% CI 0.38 to 0.77, P<0.001) [2]. A separate randomized controlled trial published in Clinical Infectious Diseases (N=361) demonstrated that TA-1 increased the rate of sputum culture conversion in patients with multidrug-resistant tuberculosis, with conversion rates of 71.8% vs. 55.9% in the placebo arm at 24 weeks [3].

These findings explain the clinical interest from prescribers, but they do not translate into FDA approval. Researchers and clinicians working in the U.S. Must manage the compounding pathway to access the peptide legally.

Why South Carolina Specifically?

State pharmacy boards hold independent authority to regulate compounding practices within their borders. South Carolina's Board of Pharmacy operates under Title 40, Chapter 43 of the South Carolina Code of Laws and has adopted rules that align closely with, but do not simply mirror, federal USP standards. A patient in Charleston asking about TA-1 faces both federal constraints and the specific rules the South Carolina Board of Pharmacy has promulgated for sterile compounding.

Federal Legal Framework: FDA, Scheduling, and the Bulks List

Not a Controlled Substance

The Drug Enforcement Administration's controlled substance schedules (Schedules I through V) govern drugs with abuse potential under the Controlled Substances Act [4]. Thymosin Alpha-1 does not appear in any DEA schedule. A South Carolina physician prescribing TA-1 does not need to hold a DEA registration for that specific prescription, nor does the patient face any schedule-based possession restriction.

FDA Approval Status

The FDA's drug approval database contains no approved new drug application (NDA) or biologics license application (BLA) for thymalfasin in the United States [5]. The agency has granted Zadaxin orphan drug designation for certain indications, and SciClone submitted a BLA in 2010 that the FDA did not approve, citing the need for additional Phase 3 data. No subsequent approval has been granted.

Because TA-1 is not an approved drug, it cannot be legally marketed or sold as a finished pharmaceutical in U.S. Commerce outside of clinical trials under an investigational new drug (IND) application.

The 503A and 503B Compounding Pathway

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound drugs for individual patients when a valid prescription exists, when the compound is not commercially available as an FDA-approved product, and when the active ingredient is either on the FDA's 503A bulks list or is not prohibited from use in compounding [6].

Section 503B covers outsourcing facilities, larger operations that can compound without a patient-specific prescription for office-use distribution [7].

Thymosin Alpha-1 is not currently on the FDA's Category 1 list of bulk drug substances that may be used in compounding (which would mean affirmative approval for bulk use). It is also not on the FDA's "Category 2" list, the list of substances nominated for consideration but found to be inappropriate for compounding. The critical practical point: because TA-1 is not on the negative/prohibited list, 503A compounding pharmacies may use it as a bulk substance to fill patient-specific prescriptions while the FDA's nomination review process remains pending [8].

The FDA's guidance document "Policy for Bulk Drug Substances Used in Compounding Under Section 503A" explains this interim framework directly, stating that substances not yet evaluated may continue to be used by 503A pharmacies pending final agency determination [8].

The 2023 Peptide Bulks List Action

In October 2023, the FDA finalized a rule placing several peptides, including BPC-157, TB-500 (thymosin beta-4), and several others, on the list of bulk substances that may not be used in 503A or 503B compounding [9]. Thymosin Alpha-1 was NOT included in that final rule. This is a legally meaningful distinction. TA-1 remained outside the prohibited list, which is why compounding pharmacies have continued to fill TA-1 prescriptions through 2024 and into 2025.

Prescribers and patients should monitor FDA docket No. FDA-2013-N-1525 for any future rulemaking that could change this status [9].

South Carolina State Law: What the Board of Pharmacy Requires

Title 40, Chapter 43 and USP <797>

South Carolina law requires all sterile compounded preparations, and TA-1 is always supplied as a sterile lyophilized powder for subcutaneous injection, to comply with USP Chapter <797> standards for sterile compounding [10]. These standards govern clean-room classification, beyond-use dating, sterility testing, and personnel training.

A 503A pharmacy licensed by the South Carolina Board of Pharmacy and meeting USP <797> requirements may legally prepare patient-specific TA-1 vials when presented with a valid prescription from a licensed South Carolina prescriber.

What Makes a Prescription "Valid" in South Carolina?

South Carolina's medical practice act (Title 40, Chapter 47) requires a valid prescriber-patient relationship before any prescription, including for compounded peptides, can be issued [11]. The South Carolina Board of Medical Examiners has clarified that telehealth consultations that meet the standard of care established in an in-person or synchronous video encounter satisfy this requirement.

For TA-1 specifically, the prescriber should document:

• A clinical indication supported by the patient's history and examination findings
• The absence of an FDA-approved therapeutic equivalent that would serve the same purpose
• Informed consent noting that TA-1 is not FDA-approved in the United States
• Planned monitoring parameters and follow-up schedule

Without this documentation, the prescription is legally vulnerable. A pharmacy presented with a TA-1 prescription may decline to fill it if the clinical rationale is absent from the chart or if the prescriber cannot demonstrate a legitimate prescriber-patient relationship.

Out-of-State Compounding Pharmacies Shipping Into South Carolina

Many patients access TA-1 through compounding pharmacies based in other states. A pharmacy shipping a compounded sterile preparation into South Carolina must hold a valid non-resident pharmacy permit issued by the South Carolina Board of Pharmacy [12]. Patients who order TA-1 from an out-of-state pharmacy should verify that the pharmacy holds this permit. The South Carolina Board of Pharmacy maintains a public license-lookup tool at llr.sc.gov.

Pharmacies that lack this permit are operating outside South Carolina law. Receiving a shipment from such a pharmacy does not expose the patient to criminal liability in most circumstances, but the pharmacy itself is operating unlawfully, which raises questions about oversight of sterile compounding quality.

Who Can Prescribe Thymosin Alpha-1 in South Carolina?

Licensed Prescribers

Any of the following South Carolina-licensed practitioners may prescribe TA-1 within their scope of practice:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) licensed under Title 40, Chapter 47
• Nurse practitioners (NP) with full practice authority under S.C. Code § 40-33-34
• Physician assistants (PA) operating under a supervising physician's delegation agreement

Prescribing TA-1 outside a documented clinical indication or without a prescriber-patient relationship constitutes a violation of the medical practice act and may result in disciplinary action by the respective licensing board.

Telehealth Access

South Carolina enacted broad telehealth parity legislation in 2021 (S.C. Code § 38-71-280), requiring that health insurers cover telehealth services at parity with in-person care [13]. A patient in Columbia, Greenville, or Myrtle Beach can establish care with a telehealth prescriber via synchronous video, receive a TA-1 prescription if clinically indicated, and have that prescription filled by a permitted South Carolina compounding pharmacy, without ever visiting a brick-and-mortar clinic.

The telehealth encounter must meet the same standard of care as an in-person visit. A prescriber who issues a TA-1 prescription after a five-minute asynchronous text questionnaire without a full history, review of labs, and documented indication is not meeting that standard.

Clinical Context: What TA-1 Is Actually Used For

The following framework summarizes the evidence tiers that most HealthRX-affiliated clinicians use when evaluating whether TA-1 is appropriate for a given patient. This is not a published guideline, it reflects the clinical reasoning applied in our physician-reviewed intake process.

Tier 1 (strongest evidence): Chronic viral hepatitis, sepsis adjunct therapy. The JAMA Network Open meta-analysis cited above (N=3,512) and a 2018 Cochrane-style systematic review in Frontiers in Immunology covering 22 trials in chronic hepatitis B (N=2,481) support these indications [14]. Effect sizes are meaningful and consistent across populations.

Tier 2 (moderate evidence): Post-infectious immune dysfunction, adjuvant cancer immunotherapy. A Phase 2 randomized trial in Cancer Immunology Research (N=120) found that TA-1 combined with chemotherapy improved CD4+ T-cell recovery at 90 days post-treatment compared with chemotherapy alone (median CD4+ count: 487 vs. 341 cells/mm³, P<0.05) [15]. Replication in larger Phase 3 trials is pending.

Tier 3 (preliminary or mechanistic data only): Long COVID immune rehabilitation, preventive immune support in high-risk occupational groups. Case series and open-label pilot studies exist, but no randomized controlled trials with adequate power have been published as of January 2025. Prescribers should document that this use is off-label and that the evidence base is preliminary.

Standard Dosing Protocol

The dosing regimen used in the majority of published clinical trials, and the one most compounding pharmacies are calibrated to prepare, is 1.6 mg subcutaneous injection administered two to three times per week for four to six weeks, followed by a maintenance phase or rest period determined by clinical response [16]. Some protocols for sepsis adjunct therapy have used daily dosing at 1.6 mg for five to seven days in the acute setting.

Contraindications and Safety Signals

TA-1 has an unusually favorable safety profile relative to most immunomodulatory agents. No serious adverse events were reported at higher-than-expected rates in the JAMA Network Open meta-analysis (N=3,512) [2]. The most common adverse effects in trials are injection-site reactions, mild fatigue, and transient flu-like symptoms occurring in fewer than 8% of subjects.

Patients with autoimmune conditions should use TA-1 with caution, as enhanced T-cell activation could theoretically worsen immune-mediated disease. No formal contraindication exists in the published literature, but rheumatologists and endocrinologists managing autoimmune patients should be involved in the prescribing decision.

How to Get Thymosin Alpha-1 in South Carolina: A Step-by-Step Overview

Step 1: Establish Care With a Licensed Prescriber

Schedule an in-person or synchronous telehealth consultation with a South Carolina-licensed physician, NP, or PA. Bring recent labs (CBC with differential, comprehensive metabolic panel, and any relevant immune markers such as CD4/CD8 ratio or natural killer cell activity if your prescriber orders them). The prescriber will document your clinical indication.

Step 2: Confirm Pharmacy Licensure

Ask the prescriber which compounding pharmacy they use and verify that pharmacy holds a South Carolina Board of Pharmacy license (for in-state pharmacies) or a South Carolina non-resident pharmacy permit (for out-of-state compounders). Check llr.sc.gov before your first order.

Step 3: Verify Compounding Standards

Ask the pharmacy directly whether they comply with USP <797> for sterile compounding, whether they conduct third-party potency and sterility testing on each batch, and what their beyond-use dating policy is for reconstituted TA-1. A pharmacy unwilling to answer these questions directly is a pharmacy to avoid.

Step 4: Obtain the Medication and Review Storage Instructions

Lyophilized TA-1 powder should be stored at 2°C to 8°C before reconstitution. After reconstitution with bacteriostatic water, most compounding pharmacies assign a beyond-use date of 30 days when stored refrigerated. Discard any vial that appears cloudy, discolored, or has particulate matter.

Step 5: Follow Up

Return for a follow-up visit at four to six weeks. A responsible prescriber will reassess clinical response, order relevant labs if indicated (CBC with differential is reasonable), and decide whether to continue, adjust, or discontinue the protocol.

Risks of Obtaining TA-1 Outside the Legal Pathway

Purchasing TA-1 from online "research chemical" vendors who sell it labeled "not for human use" circumvents both federal and South Carolina law. The FDA has issued multiple warning letters to vendors selling peptides in this manner [17]. Preparations sold outside licensed compounding pharmacies are not subject to sterility testing, potency verification, or endotoxin testing. Injecting a preparation that fails these standards carries real risk of infection, abscess, or systemic sepsis.

Beyond safety, a South Carolina physician who recommends a specific non-licensed vendor as a substitute for a legitimate pharmacy prescription may face disciplinary action from the Board of Medical Examiners for unprofessional conduct.